Medical devices move closer to pharma in new EC structure
This article was originally published in Clinica
The medical devices and diagnostics unit within the European Commission's Directorate General Enterprise, which has traditionally been in a separate Directorate to pharmaceuticals, is now going to move into the same Directorate, still within DGE, in the New Year.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.